Security record · archived quarter
CDTX
Cidara Therapeutics, Inc. · Healthcare · Biotechnology
7Tracked holders
+1Δ holders
1.63MShares held
$35.01MReported value
+1New positions
−0Exits
Momentum inputs (comparable managers):
holder breadth +16.7% ·
share flow +30.0% ·
net new positions +14.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
Ownership over time
Who holds it · Q1 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 990.00K | +167.6% | $21.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 287.77K | New | $6.20M | 0.0% | New | 1 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 113.86K | +1751.9% | $2.45M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 92.52K | -3.2% | $1.99M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Millennium Management ✦ | 63.58K | +76.8% | $1.37M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 54.98K | +3.6% | $1.18M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 22.58K | +18.4% | $486,287 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $6.20M | 0.0% |
Exited
| No tracked exits this quarter. |
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q1 2025 ·
Methodology ·
Get this via the API